Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5912253 | Multiple Sclerosis and Related Disorders | 2014 | 7 Pages |
Abstract
Our data suggest that disease reactivation peaked during a “high risk period” between the second and the eighth month since stopping the drug. During this period no alternative treatments seemed to provide an adequate protection from disease reactivation. Though transient, this phase could be potentially dangerous, therefore we need to develop more effective strategies to deal with this challenge.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Francesca Sangalli, Lucia Moiola, Laura Ferrè, Marta Radaelli, Valeria Barcella, Mariaemma Rodegher, Bruno Colombo, Filippo Martinelli Boneschi, Vittorio Martinelli, Giancarlo Comi,